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optimal management of blood pressure and full renin–an-
giotensin blockade. But since we are not satisfied their
benefit is proven even in that setting, we do not include
corticosteroids in our main treatment recommendations in
the table or abstract of our article. What Dr Locatelli et al.
regard as ‘nihilism’, we regard as pragmatic realism
avoiding a treatment regimen with some toxicity when
evidence in favor of its use is insecure.
Unfortunately, these uncertainties will not easily be
resolved. Modern management with adequate blood
pressure control and renin–angiotensin blockade is redu-
cing proteinuria and slowing the progression of a
significant proportion of patients with IgA nephropathy.
Proof that treatments additional to this regimen are
effective will therefore require larger and more prolonged
treatment trials unless surrogate markers of progression
become more discriminatory, and our ability to define risk
of progression in individual patients becomes more
refined.
1. Locatelli et al. Steroids and IgA nephritis. Kidney Int 2006, in press.
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To the Editor: Gerntholtz et al.1 report their series of kidney
biopsies from Black African human immunodeficiency virus
(HIV)-positive patients, adding to a growing literature
suggesting HIV-associated nephropathy (HIVAN) to be less
common than originally described.2,3 They found HIV
immune complex kidney disease to be as common as
HIVAN, and describe for the first time a ‘ball-in-cup’
appearance on silver-methenamine staining or electron
microscopy caused by subepithelial deposits associated with
basement membrane reaction, placing this lesion as an
intermediate between classical post-infectious and membra-
nous glomerulonephritis.
On review of 10 Black African HIV-positive patients
biopsied in East London after July 2004, we found a similar
prevalence of HIVAN (3/10) and immune complex-mediated
glomerulonephritis with mesangial matrix increase and
crescent formation (3/10). The ‘ball-in-cup’ lesion newly
described as typical of HIV immune complex kidney disease was
apparent in only one of the three such cases on re-examining
renal tissue. Our patients were similar in age (30–45 years),
renal function (creatinine 4627620 mmol/l, mean7s.d.),
serum albumin (2879 g/l), and CD4 count (2107155 co-
pies/ml). HIV viral load was 4.2870.88 106/l, and none
were intravenous drug users or hepatitis B positive.
Unlike the Gerntholtz series in which of those known to
follow-up 58% died, the outcome was generally good (with
universally good response to anti-retroviral drugs). Despite
often advanced presentation, only one patient has died to
date after a mean 46 weeks follow-up, and of two patients
requiring hemodialysis (both with HIVAN), one has since
recovered independent renal function. In Black African
migrants living in London, similar rates of HIVAN and
immune complex-mediated kidney disease are seen to that
described in Johannesburg – the renal and patient outcome is
however very different, emphasizing the importance of
readily available anti-retroviral therapy.
1. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South
African perspective. Kidney Int 2006; 69: 1885–1891.
2. Glassock RJ, Cohen AH, Danovitch G et al. Human immunodeficiency
virus (HIV) infection and the kidney. Ann Intern Med 1990; 112: 35–49.
3. Szczech LA, Gupta SK, Habash R et al. The clinical epidemiology and
course of the spectrum of renal diseases associated with HIV infection.
Kidney Int 2004; 66: 1145–1152.
A Cove-Smith1, MT Sheaff2 and N Ashman1
1Department of Nephrology, Royal London Hospital, London, UK and
2Department of Histopathology, Royal London Hospital and Queen Mary’s
School of Medicine and Dentistry, London, UK
Correspondence: A Cove-Smith, Renal Unit, Royal London Hospital and
Queen Mary’s School of Medicine and Dentistry, London E1 1BB, UK.
E-mail: neil.ashman@bartsandthelondon.nhs.uk
Response to ‘HIVAN is increasingly
less common in HIV-positive Black
Africans living in Europe’
Kidney International (2006) 70, 1662–1663. doi:10.1038/sj.ki.5001881
The kidney biopsy experience of Cove-Smith et al.1 in an
East London setting with Black African human immuno-
deficiency virus (HIV)-positive patients is interesting in its
parallels to ours. We feel that this emphasizes the fact that
not all that is kidney disease in the context of HIV
infection is classic HIV-associated nephropathy. There are
many other forms of renal pathology which occur, empha-
sizing the need for renal biopsy to allow full clarification.
Although detailed histopathological clarification does
not carry proven therapeutic implications at this stage, we
are at present treating all those with HIV-associated
nephropathy and HIV immune complex kidney disease
with angiotensin-converting enzyme inhibitors and anti-
retroviral therapy, regardless of the CD4 count, as we feel
that the virus is involved in the pathophysiology. This
contrasts with our published experience,2 when antiretro-
viral therapies were not used as they were not available to
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